stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) EBITDA
CareDx, Inc.'s EBITDA for fiscal 2025 was −$9.1M, compared with $61.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $141.4M. Over the past ten years it has ranged from −$188.5M (fiscal 2023) to $61.1M (fiscal 2024); the current reading is higher than 82% of that period. CareDx, Inc. ranks 18th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$9.1M | — |
| FY2024 | $61.1M | — |
| FY2023 | −$188.5M | — |
| FY2022 | −$60.8M | — |
| FY2021 | −$16.7M | — |
| FY2020 | −$13.0M | — |
| FY2019 | −$17.4M | — |
| FY2018 | −$8.9M | — |
| FY2017 | −$12.7M | — |
| FY2016 | −$30.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $17.2M | (85.42%) |
| Jun 2026 | $117.8M | 1,485.53% |
| Mar 2026 | $7.4M | — |
| Dec 2025 | −$1.0M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| WGS GeneDx Holdings Corp. compare | −$65.5M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement